Download Poster (725.71 KB)

Publication

EULAR •
14 June, 2025 •
•

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Kenneth Saag , Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Kevin Byram, Herman Mann, Danielle Hammond, Sinisa Savic, Yohei Kirino , Carmelo Gurnari, Mael Heiblig, Thibault Comont, Arsene Mekinian, Mrinal Patnaik, Lachelle D. Weeks, Gary Ho, Onima Chowdhury, Adam Al-Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin-Lavialle, Peter Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster, David B. Beck

Available materials

Poster

Publication

Exposure–safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still’s disease

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients With Uncontrolled Gout (UG) and Stage 3 CKD

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials